secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001140361-26-000780
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports prelim cash $864M, sets 2026 priorities including TEBE-AM enrollment completion in 1H 2026
--------------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and marketable securities ~$864M as of Dec 31, 2025.
- TEBE-AM Phase 3 cutaneous melanoma trial enrollment completion expected 1H 2026; topline data as early as 2H 2026.
- Phase 1/2 PRAME data expected 2H 2026: brenetafusp combos in ovarian and NSCLC, initial IMC-P115C data.
- First patient in Phase 1 type 1 diabetes trial (IMC-S118AI) expected 1H 2026; autoimmune trial app for atopic dermatitis in 2H 2026.
- KIMMTRAK enters 5th year post-approval; expects moderate revenue growth driven by community and global penetration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/0001140361-26-000780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/ef20062561_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer